October 1994

Lichtenberg, Frank and Pushner, GM (1994) Ownership structure and corporate performance in Japan. Japan and The World Economy, 6 (3). 239 - 261. ISSN 0922-1425

August 2001

Van Pottelsberghe De La Potterie, B and Lichtenberg, Frank (2001) Does foreign direct investment transfer technology across borders? Review of Economics and Statistics, 83 (3). 490 - 497. ISSN 1530-9142

September 2001

Lichtenberg, Frank (2001) Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Affairs, 20 (5). 241 - 251. ISSN 0278-2715

Lichtenberg, Frank (2001) Probing the link between gross profitability and R&D spending. Health Affairs, 20 (5). 221 - 222. ISSN 0278-2715

June 2003

Lichtenberg, Frank (2003) The effect of new drug approvals on HIV mortality in the US, 1987-1998. Economics and Human Biology, 1 (2). 259 - 266. ISSN 1570-677X

July 2004

Lichtenberg, Frank (2004) Sources of U.S. longevity increase, 1960-2001. Quarterly Review of Economics and Finance, 44 (3). 369 - 389. ISSN 1062-9769

December 2005

Lichtenberg, Frank (2005) Pharmaceutical innovation and the burden of disease in developing and developed countries. Journal of Medicine and Philosophy, 30 (6). 663 - 690. ISSN 0360-5310

August 2006

Lichtenberg, Frank (2006) The impact of increased utilization of HIV drugs on longevity and medical expenditure: An assessment based on aggregate US time-series data. Expert Review of Pharmacoeconomics and Outcomes Research, 6 (4). 425 - 436. ISSN 1473-7167

Lichtenberg, Frank (2006) Did CMS' functional equivalence decision result in equitable payments? Journal of Pharmaceutical Finance, Economics and Policy, 15 (1). 7 - 20. ISSN 1538-5698

December 2006

Lichtenberg, Frank (2006) The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: State-level evidence from 1997 to 2003. PharmacoEconomics, 24 (S3). 5 - 25. ISSN 1170-7690

September 2007

Jönsson, B, Lichtenberg, Frank and Wilking, N (2007) Reply to 'Not credible: A subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Annals of Oncology 2007, vol 18, Suppl 3, pp1-75)' by Michel P Coleman. Annals of Oncology, 18 (9). 1585 - 1587. ISSN 0923-7534

1 August 2011

Lichtenberg, Frank (2011) Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being. Health Affairs, 30 (8). 1539 - 1544. ISSN 0278-2715

1 January 2013

Lichtenberg, Frank (2013) The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000-2007. Social Science and Medicine, 77 (1). 50 - 59. ISSN 0277-9536

2014

Lichtenberg, Frank (2014) The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997–2010. Journal of Human Capital, 8 (4). 432 - 480. ISSN 1932-8575

Lichtenberg, Frank and Pettersson, B (2014) The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: Evidence from longitudinal, disease-level data. Economics of Innovation and New Technology, 23 (3). 239 - 273. ISSN 1043-8599

Lichtenberg, Frank (2014) The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000-2009. Economics and Human Biology, 13 (1). 107 - 127. ISSN 1570-677X

Lichtenberg, Frank, Tatar, M and Çalişkan, Z (2014) The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999-2010. Health Policy, 117 (3). 361 - 373. ISSN 0168-8510

March 2014

Lichtenberg, Frank (2014) Has medical innovation reduced cancer mortality? CESifo Economic Studies, 60 (1). 135 - 177. ISSN 1610-241X

Lichtenberg, Frank (2014) Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000-2009. Health Policy and Technology, 3 (1). 36 - 58. ISSN 2211-8837

1 December 2014

Lichtenberg, Frank (2014) Erratum to "Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000-2009" [Health Policy Technol. 3 (2014) 36-58]. Health Policy and Technology, 3 (4). 344 - 344. ISSN 2211-8837

2015

Lichtenberg, Frank (2015) The impact of cardiovascular drug innovation on the longevity of elderly residents of Switzerland, 2003-2012. Nordic Journal of Health Economics. ISSN 1892-9710

Lichtenberg, Frank (2015) Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995–2010. International Journal of the Economics of Business, 22 (2). 277 - 299. ISSN 1357-1516

April 2015

Lichtenberg, Frank (2015) The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997–2010. Applied Health Economics and Health Policy, 13 (2). 207 - 222. ISSN 1175-5652

Hostenkamp, G and Lichtenberg, Frank (2015) The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence. Social Science and Medicine, 130. 162 - 171. ISSN 0277-9536

September 2015

Lichtenberg, Frank (2015) The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011. International Journal of Health Economics and Management, 15 (3). 339 - 359. ISSN 2199-9023

June 2016

Lichtenberg, Frank (2016) The Benefits of Pharmaceutical Innovation: Health, Longevity, and Savings. Project Report. Montreal Economic Institute, Canada.

September 2016

Lichtenberg, Frank (2016) The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995–2012. European Journal of Health Economics, 17 (7). 833 - 854. ISSN 1618-7598

June 2017

Lichtenberg, Frank, Tatar, M and Çalışkan, Z (2017) The impact of pharmaceutical innovation on health outcomes and utilization in Turkey: A re-examination. Health Policy and Technology, 6 (2). 226 - 233. ISSN 2211-8837

September 2017

Lichtenberg, Frank (2017) The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia. Economic Record, 93 (302). 353 - 378. ISSN 0013-0249